Welcome to our dedicated page for ARCH BIOPARTNERS ORD news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on ARCH BIOPARTNERS ORD stock.
Arch Biopartners Inc. (OTCQB: ACHFF) is a clinical-stage biopharmaceutical company focused on developing new therapies for the prevention of inflammation and acute organ injury. Their primary area of research targets the dipeptidase-1 (DPEP-1) pathway, which plays a crucial role in inflammation in the lungs, kidneys, and liver.
The Company's leading drug candidate, LSALT peptide, aims to treat and prevent cardiac surgery-associated acute kidney injury (CS-AKI), a significant complication following cardiac surgeries, particularly those involving cardiopulmonary bypass. LSALT peptide has received approval for Phase II trials in several countries, including Turkey and Canada. Arch Biopartners is also exploring other potential applications for LSALT peptide, such as treating inflammation caused by SARS-CoV-2 virus infection.
In their latest developments, Arch Biopartners announced several milestones, including:
- Approval from the Turkish Ministry of Health and Health Canada for Phase II trials targeting CS-AKI.
- Patient recruitment and dosing have begun in Turkey, with participation from multiple hospital sites.
- Collaboration with major research institutions like the University of Calgary's Cumming School of Medicine and the University Health Network in Toronto.
- Publication of Phase II trial results for LSALT Peptide in the British Medical Journal Open detailing its efficacy in reducing inflammation.
Arch Biopartners operates with a robust intellectual property portfolio and actively collaborates with leading researchers and institutions to advance their drug candidates. The Company has 62,755,633 common shares outstanding and provides detailed investor information and scientific publications on their website.
Arch Biopartners Inc. (OTCQB: ACHFF) announced a successful increase in the maximum daily dose of its lead drug candidate, LSALT peptide, to 20 mg in a human trial in Australia. This trial confirmed the safety and tolerability of the new dosage, paving the way for a Phase II trial aimed at treating cardiac surgery-associated acute kidney injury (CS-AKI). Previously, LSALT peptide was administered at a maximum of 5 mg during a Phase II trial for COVID-19 patients. Arch is also advancing the production of 10,000 vials of LSALT peptide for future non-COVID trials, expected to be ready by May 2023. The trial took place at the Alfred Hospital in Melbourne, involving sixteen healthy volunteers. The new safety data will be included in a future IND application to the U.S. FDA.
Arch Biopartners Inc. (ACHFF) announced a significant partnership with the National Research Council of Canada Industrial Research Assistance Program, receiving up to $4,000,000 to enhance the LSALT peptide (Metablok) program aimed at treating acute inflammation in critical organs. The funding will support essential research tasks including dosing studies, Phase III human trials for COVID-19, and Phase II trials for cardiac surgery-related kidney injury. This initiative is expected to propel the drug development process over the next twelve months, with the project term concluding on March 31, 2024.
Arch Biopartners Inc. announced the receipt of a CIHR Project Grant of $1,109,250 for research into dipeptidase-1 (DPEP-1) and its connections to renal inflammation and chronic kidney disease (CKD). The award was given to a team led by Dr. Daniel Muruve at the University of Calgary, who is also Chief Science Officer at Arch. This funding will support efforts to understand how DPEP-1 influences kidney disease, potentially leading to new therapeutic targets. Arch is focused on innovative treatments for organ inflammation, aiming to improve outcomes for conditions like acute kidney injury.
Arch Biopartners Inc. has appointed Mr. Farris Smith from Novo Nordisk Canada Inc. as a Strategic Advisor to enhance corporate activities and business development for their drug candidates. Farris Smith brings extensive experience from various roles within Novo Nordisk, including CFO for Canada. He expressed enthusiasm for collaborating with Arch to advance their innovative treatments targeting organ inflammation. Arch Biopartners is focused on developing therapies for lung, liver, and kidney inflammation through the DPEP-1 pathway. The company currently has 62,330,292 common shares outstanding.
FAQ
What is the current stock price of ARCH BIOPARTNERS ORD (ACHFF)?
What is the market cap of ARCH BIOPARTNERS ORD (ACHFF)?
What is Arch Biopartners Inc. focused on?
What is LSALT peptide?
What recent approvals has Arch Biopartners received for LSALT peptide?
Which hospitals are participating in the Phase II trials for LSALT peptide?
What are some key findings from the Phase II trial for LSALT peptide?
What is cardiac surgery-associated acute kidney injury (CS-AKI)?
How does LSALT peptide work?
Has Arch Biopartners published any scientific papers?
How many shares does Arch Biopartners have outstanding?
Where can I find more information about Arch Biopartners?
